Mingxin China Growth Fund
VC Fund
Beijing, China
Mingxin China Growth Fund is a venture capital firm specializing in growth and expansion stage investments. The firm typically invests in telecommunication, media, technologies; consumer goods and services; healthcare, pharmaceuticals and biotech; clean tech; advanced manufacturing; agriculture; education; and business and financial servicessectors. It seeks to invest in companies based in China. Mingxin China Growth Fund is based in Beijing, China with additional offices in Shanghai, China; Shandong, China; Central, Hong Kong; and Palo Alto, California.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Mingxin China Growth Fund invests in
Stages Mingxin China Growth Fund invests in
Countries Mingxin China Growth Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jim Boettcher
|
|||
Investment Focus
Industry
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Pharmaceutical 2 (50%)
- Internet 1 (25%)
- Software 1 (25%)
Stage
- Series C 1 (25%)
- Funding Round 1 (25%)
- Private Equity 1 (25%)
- Post-IPO Equity 1 (25%)
Country
- China 2 (50%)
- United States 2 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jim Boettcher
Co-Founder & Chairman Investment Committee
|
Co-Founder & Chairman Investment Committee | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vor Biopharma
|
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) Tcells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies. | $175M / Post-IPO Equity / Jun 24, 2025 | |
Remegen
|
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates(ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California. | Private Equity / Dec 07, 2019 | |
PegBio
|
Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an agonist of glucagon-like peptide 1 (GLP-1), allows diabetes patients to take medicine once a week, instead of requiring daily injections. | $992K / Series C / Oct 15, 2015 | |
ASSIA
|
ASSIA, Inc provides broadband and Wi-Fi performance monitoring, management and optimization software to internet service providers (ISP), communications regulators, and wholesalers so they can improve customer quality of experience and satisfaction, reduce costs through operational efficiencies and increase revenues with new multi-media services. | $10M / Nov 02, 2009 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Mingxin China Growth Fund invest in?
Mingxin China Growth Fund invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series C and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mingxin China Growth Fund?
Public channels for Mingxin China Growth Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mingxin China Growth Fund?
The team at Mingxin China Growth Fund includes Jim Boettcher (Co-Founder & Chairman Investment Committee). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
